ACADIA Pharmaceuticals Inc (MEX:ACAD) Stock Price, Trades & News

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	16.76
Equity-to-Asset	0.78
Debt-to-Equity	0.04
Debt-to-EBITDA	0.55
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	7.22	Distress Grey Safe
Beneish M-Score	-1.16	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	25.4
	3-Year Book Growth Rate	42.9
	Future 3-5Y Total Revenue Growth Rate Estimate	13.3

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	0.01
	9-Day RSI	0.2
	14-Day RSI	0.57
	3-1 Month Momentum %	-14.55
	6-1 Month Momentum %	-14.55
	12-1 Month Momentum %	-24.95

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.59
	Quick Ratio	3.48
	Cash Ratio	2.79
	Days Inventory	112.87
	Days Sales Outstanding	39.05
	Days Payable	64.94

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.7
	Shareholder Yield %	-1.2

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	91.47
	Operating Margin %	7.39
	Net Margin %	34.3
	EBITDA Margin %	8.46
	FCF Margin %	19.53
	OCF Margin %	11.52
	ROE %	37.71
	ROA %	27.39
	ROIC %	20.03
	3-Year ROIIC %	74.28
	ROC (Joel Greenblatt) %	145.61
	ROCE %	7.65
	Years of Profitability over Past 10-Year	2
	Moat Score	6
	Tariff Resilience Score	7

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	11.51
	Forward PE Ratio	53.56
	PE Ratio without NRI	11.51
	Price-to-Owner-Earnings	13.84
	PS Ratio	3.96
	PB Ratio	3.47
	Price-to-Tangible-Book	3.8
	Price-to-Free-Cash-Flow	20.34
	Price-to-Operating-Cash-Flow	34.78
	EV-to-EBIT	43.69
	EV-to-Forward-EBIT	64.97
	EV-to-EBITDA	38.13
	EV-to-Forward-EBITDA	59.02
	EV-to-Revenue	3.23
	EV-to-Forward-Revenue	2.84
	EV-to-FCF	16.64
	Price-to-GF-Value	1.01
	Price-to-Projected-FCF	5.35
	Price-to-Median-PS-Value	0.46
	Price-to-Graham-Number	1.39
	Price-to-Net-Current-Asset-Value	5.86
	Price-to-Net-Cash	8.76
	Earnings Yield (Greenblatt) %	2.29
	FCF Yield %	4.9

GF Value™: MXN357.71

MEX:ACAD

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with ACAD. Try a 7-Day Free Trial to check it out.

ACADIA Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

ACADIA Pharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (MXN)
Third quarter earnings conference call for 2026	2026-11-05 16:30	In 130 days
Third quarter earnings results for 2026	2026-11-05	In 129 days
Second quarter earnings conference call for 2026	2026-08-06 16:30	In 39 days
Second quarter earnings results for 2026	2026-08-06	In 38 days
General meeting for 2026	2026-05-29 07:45	382.00 (+0.00%)
First quarter earnings conference call for 2026	2026-05-06 16:30	381.00 (+0.00%)
First quarter earnings results for 2026	2026-05-06	381.00 (+0.00%)
Guidance call for 2026	2026-03-17 08:00	447.05 (+0.00%)
Annual report for 2025	2026-02-26	447.05 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-02-25 16:30	447.05 (+0.00%)

Show

Entries

Press Release

	Subject	Date
	DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP	2026-06-26
	Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career	2026-04-30
	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences	2026-04-28
	Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting	2026-04-17
	Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026	2026-04-15
	Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome	2026-04-07
	Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum	2026-03-12
	Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors	2026-03-03
	Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome	2026-03-02
	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview	2026-02-25

10/Page

Articles on ACADIA Pharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.